

1	2	3	4	5
5.	M/s Wockhardt Ltd	Tryptomer 25mg Tablet	3.55	
6.	M/s Abbott Healthcare Pvt Ltd	Gardenal 60 Tablets	0.79	
7.	M/s Scott Edil Pharmacia	Aziphar suspension	0.05	
8.	M/s IPCA Labs	Perinorm syrup 30 ml	0.52	
9.	M/s Baxter India Pvt Ltd	Dextrose 5% Injection	0.02	0.02
10.	M/s FDC Ltd	Zathrin 500 Tablet	0.23	
11.	M/s Novartis Pharma	Voveran	28.18	
12.	M/s Biological Evans	Bert Tetanus	33.28	
13.	M/s IPCA Laboratories	HCQS Tablets	2.33	
TOTAL			126.38	54.01
<i>Suo-moto</i> payments received from various companies				0.57
Total amount recovered under DPCO, 2013				54.58

As on 28.11.2014, an amount of ₹54.58 crore has been recovered. The overcharged amount recovered from the companies, is deposited in the Consolidated Fund of India.

Manufacturing of generic medicines

†3038. SHRI PRABHAT JHA: Will the Minister of CHEMICALS AND FERTILIZERS be pleased to state:

- whether licence is not required for manufacturing of generic medicines in the country;
- if so, the details thereof;
- whether companies manufacture medicines even if the quality regulatory facilities for manufacturing the medicines is not there as there is no necessity of taking the license;
- whether there is any agency with Government to curb this situation; and
- if so, the details thereof?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI HANS RAJ GANGARAM AHIR): (a) to (e) Drugs cannot be

† Original notice of the question was received in Hindi.

manufactured for sale in the country without a Licence granted by the State Licensing Authorities appointed by respective State Governments, under the provisions of Drugs and Cosmetics Act, 1940 and Rules, 1945 made thereunder. The manufacture for sale of drugs is regulated through a system of inspection and licensing and regular inspections thereafter. The drug manufacturer is required to comply with the conditions of license and follow Good Manufacturing Practices (GMP) to ensure that the drugs manufactured by them are of standard quality.

Rates of medicines at Jan Aushadhi Stores

3039. SHRI PALVAI GOVARDHAN REDDY: Will the Minister of CHEMICALS AND FERTILIZERS be pleased to state:

- (a) whether it is a fact that Jan Aushadhi Stores proposed to supply 361 generic medicines;
- (b) if so, whether it is also a fact that even after six years of its implementation, the Ministry has not finalized rates for more than 100 medicines, if so, the reasons therefor; and
- (c) who is responsible for this and what action the Ministry has taken in this regard?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI HANS RAJ GANGARAM AHIR): (a) Yes, Sir. Under the New Business Plan, approved in 2013, 361 generic medicines are proposed to be supplied under the Jan Aushadhi Scheme.

(b) and (c) The Jan Aushadhi scheme, as originally conceived in 2008 provided for procurement of supplies only from CPSUs. However, since the CPSUs were having in-house manufacturing capability for only 138 medicines out of 361 medicines proposed to be supplied from Jan Aushadhi stores, the Department of Pharmaceuticals after reviewing the entire scheme in August, 2013 provided for procurement of medicines from private manufacturers in respect of medicines which the CPSUs are not in a position to supply.

After the approval of New Business Plan, an immediate action was initiated by Bureau of Pharma Public Sector Undertakings of India (BPPI), implementing agency for the Scheme, by floating tender for procurement of medicines from private manufacturers following the GFR and CVC guidelines. After floating two tenders, rate Contracts/price fixation has been finalized in respect of 259 medicines. The medicines in respect of the remaining items which could not be finalized on account of either single quote or no quote, are being retendered.